Skip to main content
SpringerLink
Log in

MHC Class I Gene Expression by Tumors: Immunotherapeutic Implications

  • Conference paper
Genetics of Immunological Diseases

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 137))

  • 93 Accesses

Abstract

An anti-tumor role has been established for macrophages (Fidler 1974; Fernandez-Cruz et al. 1985), NK cells (Talmadge et al. 1980; Kawase et al. 1982), and helper T cells (Fugiwara et al. 1984; Greenberg et al. 1985) in various experimental systems, but an optimal immune defense against tumor cell growth in vivo depends on the ability of cytotoxic T lymphocytes (CTLs) to recognize and destroy malignant cells (Dailey et al. 1984; Rosenstein et al. 1984). This recognition involves an interaction between the effector cell and antigens present on the tumor cell in association with MHC class I molecules (Zinkernagel et al. 1979). The MHC class I molecules are composed of a heavy glycoprotein chain of 45 kilodaltons (kD) and a noncovalently-associated beta-2 microglobulin molecule of 15 kD (Hood et al. 1983). The heavy chain is highly polymorphic and is encoded by the H-2K, D and L loci in the mouse, and by the HLA-A, -B and -C loci in human. Virtually all normal cells display class I molecules (Daar et al. 1984), as do many tumor cells. Active immuno-surveillance in vivo may select for tumor variants with altered or down-regulated class I antigens, and reduced class I gene expression by tumors may provide a means of avoiding destruction by cytotoxic T lymphocytes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ascher A, Mule JJ, Weber JS, Krosnick J, Rosenberg SA. (unpublished results)

    Google Scholar 

  • Bahler DW, Lond EM. (1985) Dimethyl sulfoxide induces expression of H-2 antigens on mouse lung carcinoma cells. J Immunol 134: 2790.

    PubMed  CAS  Google Scholar 

  • Baker DW, Frelinger JG, Harwell LW, Lord EM. (1987) Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection. Proc Natl Acad Sci USA 84: 4562

    Article  Google Scholar 

  • Bernards R, Dessain SK, Weinberg RA. (1986) N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47: 667

    Article  PubMed  CAS  Google Scholar 

  • Burgert HG, Kvist S. (1985) An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 41: 987.

    Article  PubMed  CAS  Google Scholar 

  • Csiba A, Whitwell HL, Moore M. (1984) Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer 50: 699

    Article  PubMed  CAS  Google Scholar 

  • Daar AS, Fuggle SU, Fabre JW, Ting A, Morris PJ. (1984) The detailed description of HLA-A, -B and -C antigens in normal human organs. Transplant 38: 287

    Article  CAS  Google Scholar 

  • Dailey MO, Pillemer E, Weissman IL. (1984) Protection against syngeneic lymphoma by a long lived cytotoxic T cell alone. Proc Natl Acad Sci USA 79: 5384

    Article  Google Scholar 

  • Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA. (1984) The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol 132: 2123

    PubMed  CAS  Google Scholar 

  • Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttita F, Mulshine J, Binon P, Minna J. (1985) Markedly decreased expression of class I histocompatibility antigens, protein and mRNA in human small cell lung cancer. J Exp Med 161: 1135

    Article  PubMed  CAS  Google Scholar 

  • Ferguson A, Moore M, Fox H. (1985) Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: An immunohistochemical analysis of the tumor cells and infiltrating lymphocytes. Br J Cancer 52: 551

    Article  PubMed  CAS  Google Scholar 

  • Fernandez-Cruz E, Ulich T, Schreiber RD. (1985) In vivo activity of lymphokine-activated macrophages in host defense against neoplasia. J Immunol 134: 3489

    PubMed  CAS  Google Scholar 

  • Festenstein H, Schmidt W. (1981) Variation in MHC antigenic profiles of tumor cells and its biologic effects. Immunol Rev 60: 85

    Article  PubMed  CAS  Google Scholar 

  • Fidler IJ. (1974) Inhibitors of pulmonary metastases by intravenous injection of specifically activated macrophages. Cancer Res 34: 1074

    PubMed  CAS  Google Scholar 

  • Fleming KA, McMichaeal A, Morton JA, Woods J, McGee JOD. (1981) Distribution of HLA class I antigens in normal human tissue and in mammary cancer. Clin Path 34: 779

    Article  CAS  Google Scholar 

  • Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. (1984) The role of tumor specific Lyt-1+2− T cells in eradicating tumor cells in vivo. J Immunol 133: 1671

    PubMed  CAS  Google Scholar 

  • Fukusato T, Gerber MA, Thung ST, Ferrone S, Schaffner F. (1986) Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol 123: 264

    PubMed  CAS  Google Scholar 

  • Gracomini P, Aguzzi A, Pestka S, Fisher PB, Ferrone S. (1984) Modulation by recombinant DNA leucocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA and tumor associated antigens by human melanoma cells. J Immunol 133: 1649

    Google Scholar 

  • Greenberg PD, Kern DF, Cheever MA. (1985) Therapy of disseminated murine leukemia with cyclophosphamide and Lyt1+2− T cells. J Exp Med 161: 1122

    Article  PubMed  CAS  Google Scholar 

  • Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. (1982) Lymphoklne activated killer phenomenon: lysis of natural killer-resistant fresh solid tumor cells by Interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823

    Article  PubMed  CAS  Google Scholar 

  • Haddada H, Lewis AM, Sogn JA, Coligan JE, Cook JL, Walker TA, Levine AS. (1986) Tumorigenicity of hamster and mouse cells transformed by adenovirus types 2 and 5 is not influenced by the level of class I major histocompa tibility antigens expressed on the cells. Proc Natl Acad Sci USA 83: 9684

    Article  PubMed  CAS  Google Scholar 

  • Halloran PF, Jephthah-Ochola J, Urmson J, Farkas S. (1985) Systemic immunologic stimuli increase class I and class II antigen expression in mouse kidney. J Immunol 135: 1053

    PubMed  CAS  Google Scholar 

  • Hart DNJ, Newton MR, Reece-Smith H, Fabne JW, Morris PJ. (1983) Major histocompatibility complex antigens in the rat pancreas, isolated pancreatic islets, and adrenal glands. Transplant 36: 431

    Article  CAS  Google Scholar 

  • Hayashi H, Tanaka K, Jay F, Khoury G, Jay G. (1985) Modulation of the tumorigenicity of human adenovirus-12 transformed cells by interferon. Cell 43: 263

    Article  PubMed  CAS  Google Scholar 

  • Hood L, Steinmetz B, Malissen B. (1983) Genes of the major histocompatibility complex of the mouse. Ann Rev Immunol 1: 529

    Article  CAS  Google Scholar 

  • Hui K, Grosveld F, Festenstein H. (1984) Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311: 750

    Article  PubMed  CAS  Google Scholar 

  • Israel A, Kimura A, Fournier A, Fellous M, Kourilsky P. (1986) Interferon response sequence potentiates activity of an enhancer in the promoter region of a mouse H-2 gene. Nature 322: 743

    Article  PubMed  CAS  Google Scholar 

  • Jones EA, Bodmer WF. (1980) Lack of expression of HLA antigens on choriocarcinoma cell lines. Tissue Antigens 16: 195

    Article  PubMed  CAS  Google Scholar 

  • Kawase I, Urdahl DL, Brooks CG, Henney CS. (1982) Selective depletion of NK cell activity in vivo and its effect on the growth of NK sensitive and NK resistant tumor cell variants. Int J Cancer 29: 567

    Article  PubMed  CAS  Google Scholar 

  • Lampson LA, Fisher CA, Whelan JP. (1983) Striking paucity of HLA-A, B, and C and B2-microglobulin on human neuroblastoma cell lines. J Immunol 130: 2471

    PubMed  CAS  Google Scholar 

  • Lindahl P, Leary P, Gresser I. (1973) Enhancement by interferon of the expression of surface antigens of murine leukemia L1210 cells. Proc Natl Acad Sci USA 70: 2785

    Article  PubMed  CAS  Google Scholar 

  • Ljunggren HG, Karre K. (1985) Host resistance directed selectively against H-2 deficient lymphoma variants. Analysis of the mechanism. J Exp Med 162: 1745

    Article  PubMed  CAS  Google Scholar 

  • Ljunggren HG, Karre K. (1986) Variations in MHC Antigen expression on tumors and its significance. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression opposing influences of T cell and natural killer mediated resistance. J Immunogenet 13: 141

    Article  PubMed  CAS  Google Scholar 

  • Masucci MG, Torsteindottin S, Colombanl J, Brautbai C, Klein E, Klein G. (1987) Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkett lymphoma lines. Proc Natl Acad Sci USA 84: 4567

    Article  PubMed  CAS  Google Scholar 

  • Momberg F, Degeher T, Bacchus E, Moldenhauer G, Hammerling GJ, Moller P. (1986) Loss of HLA-A, -B, -C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 37: 179

    Article  Google Scholar 

  • Mule JJ, Yang JC, Shu S, Lafreniere R, Rosenberg SA. (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol 139: 285

    PubMed  CAS  Google Scholar 

  • Mule JJ, Yang J, Shu S, Rosenberg SA. (1986) The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136: 3899

    PubMed  CAS  Google Scholar 

  • Nanni P, Colombo M, DeGiovanni C, Lollini P, Nicoletti G, Parmiani G, Prodi G. (1983) Impaired H-2 expression in BL6 melanoma variants. J Immunogenet 10: 361

    Article  PubMed  CAS  Google Scholar 

  • Natali PG, Bigotti A, Cavaliere R, Liao S-K, Taniguchi M, Matsui M, Ferrone S. (1985) Heterogeneous expression of melanoma associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res 45: 2883

    PubMed  CAS  Google Scholar 

  • Natali PG, Bigotti A, Nicotra NR, Viona M, Manfredi D, Ferrone S. (1984) Distribution of human class I (HLA-A, -B, -C) histocompatibility antigens in normal and malignant tissues of non-lymphoid origin. Cancer Res 44: 4679

    PubMed  CAS  Google Scholar 

  • Paul LC, Paradyusz JM, Milford EM, Kunz HW, Carpenter CB. (1982) Expression of RT 1.A and RT 1.B/D antigens on endothelium of rat kidneys. Transplant 34: 121

    Article  CAS  Google Scholar 

  • Reuter DJ, Bergman W, Welaart K, Scheffer E, Van Vloten WA, Russo C, Ferrone S. (1984) Immunohistochemical analysis of malignant melanomas and nevo-cellular revi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 44: 3930

    Google Scholar 

  • Rogers M, Gooding LR, Margulies DH, Evans GA. (1983) Analysis of a defect in the H-2 genes of SV40 transformed C3H fibroblasts that do not express H-2Kk. J Immunol 130: 2418

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 316: 891

    Google Scholar 

  • Rosenstein M, Rosenberg SA. (1984) Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies. J Natl Cancer Inst 72: 1161

    PubMed  CAS  Google Scholar 

  • Scheurich P, Kronke M, Schluter C, Ucer U, Pfizenmaier K. (1986) Non-cytocidal mechanisms of action of tumor necrosis factor on human tumor cells: enhancement of HLA gene expression synergistic with IFN-gamma. Immunobiol 172: 291

    Article  CAS  Google Scholar 

  • Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, van der Eb AJ. (1983) Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305: 771

    Article  PubMed  CAS  Google Scholar 

  • Seigier HD, Kremer WB, Metzgar RS, Ward FE, Hwang AT, Amos DB. (1971) HLA antigenic loss in malignant transformation. J Natl Cancer Inst 46: 577

    Google Scholar 

  • Shiloni E, Lafreniere R, Mule JJ, Schwarz SL, Rosenberg SA. (1986) Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin-2 on established pulmonary and hepatic metastases in mice. Cancer Res 46: 5633.

    PubMed  CAS  Google Scholar 

  • Smith KA. (1980) T-cell growth factor. Immunol Rev 51: 337

    Article  PubMed  CAS  Google Scholar 

  • Solter D, Shevinsky L, Knowles BB, Strickland S. (1979) The induction of antigenic changes in a teratocarcinoma stem cell line (F9) by retinoic acid. Develop Biol 70: 515

    Article  PubMed  CAS  Google Scholar 

  • Talmadge JE, Myers KM, Prieur DJ, Starkley JR. (1980) Role of NK cells in tumor growth and metastases in beige mice. Nature 284: 622

    Article  PubMed  CAS  Google Scholar 

  • Tanaka K, Hayashi H, Hamada C, Khoury G, Jay G. (1986) Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 83: 8723

    Article  PubMed  CAS  Google Scholar 

  • Tanaka K, Isselbacher KJ, Khoury G, Jay G. (1984) Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228: 26

    Article  Google Scholar 

  • Tanaka K, Yoshioka T, Bieberich C, Jay G (1988) Role of the MHC class I antigens in tumor growth and metastasis. Ann. Rev. Immunol. (in press).

    Google Scholar 

  • Turbitt ML, Mackie RM. (1981) Loss of beta-2-microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Brit J Dermatol 104: 507

    Article  CAS  Google Scholar 

  • Wallich R, Bulbuc N, Hammerling GJ, Katsav S, Segal S, Feldman M. (1985) Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301

    Article  PubMed  CAS  Google Scholar 

  • Weber JS, Jay G, Tanaka K, Rosenberg SA. (1987) Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med (in press)

    Google Scholar 

  • Yague J, White J, Coleclough C, Kappala J, Palmer E, Marrack P. (1985) The T cell receptor: the alpha and beta chains define idiotype, antigen and MHC specificity. Cell 42: 81

    Article  PubMed  CAS  Google Scholar 

  • Zinkernagel RM, Doherty PC. (1979) MHC restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv Immunol 27: 51

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, National Cancer Institute, Bethesda, Maryland, 20892, USA

    J. S. Weber

  2. Laboratory of Molecular Virology, National Cancer Institute, Bethesda, Maryland, 20892, USA

    G. Jay

Authors
  1. J. S. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Jay
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

    Beverly Mock Ph.D  & Michael Potter M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Weber, J.S., Jay, G. (1988). MHC Class I Gene Expression by Tumors: Immunotherapeutic Implications. In: Mock, B., Potter, M. (eds) Genetics of Immunological Diseases. Current Topics in Microbiology and Immunology, vol 137. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-50059-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-50059-6_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-50061-9

  • Online ISBN: 978-3-642-50059-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation